Young Potenza’s Promise Attracts Astellas As Potential Buyer
This article was originally published in PharmAsia News
Executive Summary
Astellas has secured an option to acquire the U.S. biotech Potenza as part of a new R&D alliance focusing on immuno-oncology candidates.
You may also be interested in...
Astellas Dips Into Digital Health Via New Venture
New venture DigiTx will give Astellas a leg up in its quest to access novel digital health technologies, in a move unveiled as the Japanese firm reported continued strong growth for top product Xtandi.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Biomarin’s next chapter; Amgen’s obesity plans; Daiichi’s new ADC data; Acelyrin hit by clinical failure; and Skyrizi beats Stelara in Crohn’s.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.